Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain

Collins, 1996, J. Am. Chem. Soc., 118, 2143, 10.1021/ja9531081 Gardell, 2002, Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers, J. Neuroscience, 22, 6747, 10.1523/JNEUROSCI.22-15-06747.2002 Hruby, 1982, Conformational restrictions of biologically active peptides via amino acid side chain groups, Life Sciences, 31, 189, 10.1016/0024-3205(82)90578-1 Hruby, 2002, Designing peptide receptor agonists and antagonists, Nature Reviews Drug Discovery, 1, 847, 10.1038/nrd939 Hruby, 1990, Emerging approaches in the molecular design of receptor selective peptide ligands: Conformational, topographical and dynamic considerations, Biochem. J., 268, 249, 10.1042/bj2680249 Hruby, 1994, Analogues of cholecystokinin26–33 selective for B-type CCK receptors possess delta opioid receptor agonist activity in vitro and in vivo: Evidence for similarities in CCK-B and δ opioid receptor requirements, 669 Hruby, 1998, Chemical Synthesis of Peptides, 27 Nikiforovich, 1993, Models for the A- and B- receptor-bound conformations of CCK-8, Biochem. Biophys. Res. Commun., 194, 9, 10.1006/bbrc.1993.1777 Nikiforovich, 1991, Topographical requirements for δ-selective opioid peptides, Biopolymers, 31, 941, 10.1002/bip.360310804 Shenderovich, 2000, A three dimensional model of the opioid pharmacophore: Comparative molecular modeling of peptide and non-peptide ligands, Biopolymers, 53, 565, 10.1002/(SICI)1097-0282(200006)53:7<565::AID-BIP4>3.0.CO;2-5 Slaninová, 1991, Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide, Eur. J. Pharmacol., 200, 195, 10.1016/0014-2999(91)90688-M Vanderah, 2001, Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin, Pain, 92, 5, 10.1016/S0304-3959(01)00311-6